NCT02845882 2026-03-18
LBL-2016 for Children or Adolescents in China
Children's Cancer Group, China
Phase 3 Active not recruiting
Clinical Trials
17 trialsNCT06773936 2026-03-04
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
Phase 2 Enrolling by invitation
NCT04542824 2026-03-03
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT07029776 2026-03-03
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
University of Arkansas
Phase 2 Not yet recruiting
NCT07407140 2026-03-02
VAG-3+7-G
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Not yet recruiting
NCT06587451 2026-02-24
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
Sandoz
Phase 3 Terminated
NCT07405736 2026-02-12
Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06656598 2026-02-11
SPORADIC
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Recruiting
NCT07372365 2026-01-28
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT07207824 2025-10-06
HERO
Fudan University
Phase 3 Not yet recruiting
NCT07199855 2025-09-30
Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia
Zhejiang University
Phase 2 Active not recruiting
NCT05051631 2025-08-28
BRAVE
Vanderbilt University Medical Center
Phase NA Completed
NCT07014202 2025-07-30
Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT07094464 2025-07-30
Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation
Chinese PLA General Hospital
Phase 1 Active not recruiting
NCT05827549 2025-06-06
ReCALL
Asan Medical Center
Phase 2 Recruiting
NCT03690869 2025-04-08
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Regeneron Pharmaceuticals
Phase 1/2 Terminated
NCT05375708 2025-03-28
SIRIUS
UMC Utrecht
Phase 2 Suspended